SCHEMBL1070076

SCHEMBL1070076

O/N=C\c1ccc(O)c(O)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 6/20 0.71
BLM P54132 4/20 0.71
L3MBTL1 Q9Y468 4/20 0.71
ALPL P05186 2/20 0.71
ALPI P09923 2/20 0.71
ALPG P10696 2/20 0.71
GFER P55789 2/20 0.71
SRC P12931 1/20 0.59
LCK P06239 3/20 0.58
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
KDM4E B2RXH2 4/20 0.57
ALDH1A1 P00352 3/20 0.57
CYP1A2 P05177 2/20 0.57
LMNA P02545 2/20 0.57
TP53 P04637 2/20 0.57
MAPT P10636 2/20 0.57
HPGD P15428 2/20 0.57
ALOX15 P16050 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1070078 1.00 POLB (0.71) POLBBLML3MBTL1ALPLALPI
SCHEMBL7094871 1.00 POLB (0.71) POLBBLML3MBTL1ALPLALPI
SCHEMBL15951399 0.83 POLB (1.00) POLBBLML3MBTL1ALPLALPI
SCHEMBL17548931 0.80 L3MBTL1 (0.47) POLBBLML3MBTL1ALPLALPI
SCHEMBL28765452 0.80 L3MBTL1 (0.47) POLBBLML3MBTL1ALPLALPI
SCHEMBL17548936 0.80 LMNA (0.49) POLBBLML3MBTL1ALPLALPI
SCHEMBL17329459 0.80 L3MBTL1 (0.52) POLBBLML3MBTL1ALPLALPI
SCHEMBL17329458 0.80 L3MBTL1 (0.52) POLBBLML3MBTL1ALPLALPI
SCHEMBL23067460 0.79 POLB (0.68) POLBBLML3MBTL1ALPLALPI
SCHEMBL29557130 0.79 POLB (0.68) POLBBLML3MBTL1ALPLALPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6395260-B1 SKIN LIGHTENING COMPOSITIONS HAARMANN & REIMER GMBH (DE) 2002-05-28 US claimed
EP-1066821-A1 Topical cosmetic product containing benzaldoxims HAARMANN & REIMER GMBH (DE) 2001-01-10 EP claimed
JP-57059810-A None JP disclosed
JP-56057712-A None JP disclosed
US-11759435-B2 Dihydrochalcone derivatives influencing inflammatory states SYMRISE AG (DE) 2023-09-19 US disclosed
US-20220226261-A1 DIHYDROCHALCONE DERIVATIVES INFLUENCING INFLAMMATORY STATES SYMRISE AG (DE) 2022-07-21 US disclosed
US-10758468-B2 Solubilizer for cosmetic preparations SYMRISE AG (DE) 2020-09-01 US disclosed
EP-2633886-B1 COMPOUNDS AND MIXTURES INFLUENCING INFLAMMATORY STATES SYMRISE AG (DE) 2018-01-31 EP disclosed
WO-2017186298-A1 DIHYDROCHALCONE DERIVATIVES INFLUENCING INFLAMMATORY STATES SYMRISE AG (DE) 2017-11-02 WO disclosed
US-9481811-B2 Composition and method for polishing memory hard disks exhibiting reduced edge roll-off CABOT MICROELECTRONICS CORPORATION (US) 2016-11-01 US disclosed
US-20160244639-A1 COMPOSITION AND METHOD FOR POLISHING MEMORY HARD DISKS EXHIBITING REDUCED EDGE ROLL-OFF CMC MATERIALS LLC 2016-08-25 US disclosed
EP-1267822-A2 USE OF 3,4-DIHYDROXY-MANDELIC ACID FOR PROTECTING AGAINST OXIDATIVE DAMAGE CAUSED BY ULTRA-VIOLET LIGHT HAARMANN & REIMER GMBH (DE) 2003-01-02 EP disclosed
EP-1239825-A1 CATECHOL OXIMES AND THEIR USE IN COSMETIC AND DERMATOLOGICAL PREPARATIONS HAARMANN & REIMER GMBH (DE) 2002-09-18 EP disclosed
US-6395260-B1 SKIN LIGHTENING COMPOSITIONS HAARMANN & REIMER GMBH (DE) 2002-05-28 US disclosed
WO-2001098258-A1 3,4-DIHYDROXYMANDELIC ACID ALKYLAMIDES AND USE THEREOF HAARMANN & REIMER GMBH (DE) 2001-12-27 WO disclosed
WO-2001070176-A2 USE OF 3,4-DIHYDROXY-MANDELIC ACID FOR PROTECTING AGAINST OXIDATIVE DAMAGE CAUSED BY ULTRA-VIOLET LIGHT HAARMANN & REIMER GMBH (DE) 2001-09-27 WO disclosed
WO-2001043712-A1 CATECHOL OXIMES AND THEIR USE IN COSMETIC AND DERMATOLOGICAL PREPARATIONS HAARMANN & REIMER GMBH (DE) 2001-06-21 WO disclosed
EP-1066821-A1 Topical cosmetic product containing benzaldoxims HAARMANN & REIMER GMBH (DE) 2001-01-10 EP disclosed
JP-S5759810-A CARCINOSTATIC AGENT TOYOBO CO LTD 1982-04-10 JP disclosed
JP-S5657712-A CARCINOSTATIC AGENT TOYOBO CO LTD 1981-05-20 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10758468-B2 Solubilizer for cosmetic preparations SRPK3, SRPK1, SYMPK POLB 4255/4885BLM 2047/4885L3MBTL1 2281/4885
US-11759435-B2 Dihydrochalcone derivatives influencing inflammatory states IL17A, TNF, IL1B POLB 2486/4885BLM 2988/4885L3MBTL1 4885/4885
US-20220226261-A1 DIHYDROCHALCONE DERIVATIVES INFLUENCING INFLAMMATORY STATES IL17A, TNF, IL1B POLB 2486/4885BLM 2988/4885L3MBTL1 4885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.